Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery, has entered a collaboration and license agreement with Eli Lilly and Company to discover, develop, and commercialize molecular glue therapeutics in oncology. The collaboration will leverage Magnet’s TrueGlue discovery platform to identify molecular glues capable of inducing protein proximity and cooperativity, enabling novel mechanisms of action to address difficult-to-drug targets spanning multiple dise...